When sourcing generic medicines from India, one term appears repeatedly in regulatory documents and product listings: WHO-GMP certified. But what does this certification actually mean? How does it compare to India’s domestic quality standards under Schedule M? And why should international buyers care about the sweeping regulatory reforms underway in 2025–2026? This comprehensive guide explains everything you need to know about pharmaceutical quality assurance in India.
📋 What Is WHO-GMP Certification?
WHO-GMP (Good Manufacturing Practices) certification is an international quality standard issued by the World Health Organization. It ensures that pharmaceutical products are consistently produced and controlled according to quality standards appropriate for their intended use. A WHO-GMP certified facility must demonstrate compliance with stringent requirements covering:
- Premises and equipment — Facilities designed to prevent cross-contamination and maintain sterile conditions
- Personnel training — Qualified staff with documented training in GMP procedures
- Documentation — Complete traceability of every batch from raw material to finished product
- Quality control testing — Independent testing of raw materials, intermediates, and finished products
- Stability studies — Evidence that products remain effective throughout their shelf life
- Complaint and recall procedures — Systems to investigate quality issues and remove defective products from the market
For international buyers, WHO-GMP certification is often the minimum requirement for importing pharmaceutical products, especially for procurement by organizations such as UNICEF, UNFPA, the Global Fund, and national health programs across Africa, Asia, and Latin America.
🏭 India’s Revised Schedule M: A Game Changer for Quality Standards
India’s domestic pharmaceutical manufacturing standards are governed by Schedule M of the Drugs and Cosmetics Rules, 1945. In December 2023, the Indian government notified a completely revised Schedule M, aligning India’s domestic GMP requirements more closely with international WHO-GMP standards. This is arguably the most significant regulatory reform in Indian pharma in decades.
Key changes in the revised Schedule M include (as reported by BioSpectrum India, July 2025; Business Standard, February 2026):
- Risk management — Mandatory implementation of ICH Q9 quality risk management principles
- Pharmaceutical Quality System (PQS) — A comprehensive quality management framework instead of piecemeal compliance
- Data integrity — Strict requirements for electronic data management and audit trails
- Validation master plan — Formalized process, cleaning, and analytical method validation
- Stricter environmental monitoring — Enhanced microbial and particulate monitoring for sterile products
The revised Schedule M was given a phased implementation timeline: large pharmaceutical manufacturers (with annual turnover above ₹250 crore) were required to comply by December 2024, while medium and small manufacturers have until December 2025–June 2026, depending on their size and classification.
🔍 WHO-GMP vs. Schedule M: What’s the Difference?
Many international buyers wonder: if a manufacturer has Schedule M compliance, does it also have WHO-GMP? The short answer is: not automatically. Here’s how the two relate:
| Aspect | Schedule M (India) | WHO-GMP |
|---|---|---|
| Jurisdiction | Indian domestic law (CDSCO enforced) | International standard (WHO assessed) |
| Audit frequency | State drug authority inspections (variable) | Periodic re-assessment by WHO or authorized agency |
| Recognition | Required for sale within India | Required for international tender participation |
| Scope | Covers all drugs manufactured in India | Voluntary certification, facility-specific |
| Alignment | Revised Schedule M (2023) closely mirrors WHO-GMP | Gold standard for global procurement |
Importantly, the revised Schedule M brings Indian domestic standards much closer to WHO-GMP requirements than ever before. A facility in full compliance with revised Schedule M will meet most, if not all, WHO-GMP requirements as reported by CDSCO and DCI directives (Drishti IAS, November 2025).
🛡️ CDSCO’s Major Quality Overhaul in 2026
The Central Drugs Standard Control Organization (CDSCO), India’s national drug regulatory authority, has undertaken sweeping reforms in 2025–2026 to strengthen pharmaceutical quality oversight (as reported by Business Standard and IndiaMedToday, February 2026):
- Outsourcing GMP audits to QCI-certified agencies — CDSCO began planning to outsource GMP and GCP audits to third-party agencies certified by the Quality Council of India (QCI), expanding inspection capacity
- Building a 1,500-strong scientific cadre — The regulator plans to onboard approximately 1,500 expert reviewers to deepen technical review capacity for drug applications
- Tightened quality net for small manufacturers — Stricter enforcement actions against units producing substandard drugs, with the DCGI stating the regulator would “remove the rot” of substandard cough syrup manufacturing (Moneycontrol, February 2026)
- NOC simplification for exports — CDSCO eased No Objection Certificate requirements for shipments to Stringent Regulatory Authority (SRA) markets, streamlining export processes
These reforms signal a clear message: India is serious about shedding its reputation for quality variability and positioning itself as a trusted global pharmaceutical manufacturer.
⚠️ Extension Concerns: Small Pharma Firms Struggle to Meet Deadline
While the regulatory intent is clear, implementation on the ground has been challenging. By late 2025, thousands of small pharmaceutical manufacturers were still not fully compliant with the revised Schedule M (as reported by Mint, December 2025; KNN India, December 2025; Financial Express, December 2025):
- The government was considering a one-year extension for small manufacturers struggling to meet the compliance deadline
- The Indian Drug Manufacturers’ Association (IDMA) formally requested more time, noting that many companies had started upgrades but faced delays (Economic Times, December 2025)
- The Union Health Minister directed CDSCO and the Department of Pharmaceuticals to find a workable solution for Schedule M compliance concerns (Medical Dialogues, January 2026)
- Despite the extension debate, large manufacturers (over 80% of India’s pharmaceutical output by value) are reported to be on track for compliance
For international buyers, this means that the quality landscape is improving rapidly, but due diligence on individual manufacturers remains essential. Always verify the specific facility’s current compliance status, not just the brand name.
✅ How to Verify If an Indian Manufacturer Has Valid WHO-GMP Certification
Whether you are a procurement officer, a pharmacy owner, or an individual importing medicines for personal use, here is a practical checklist for verifying WHO-GMP compliance of an Indian manufacturer:
- Check the WHO list of prequalified products — Visit extranet.who.int/prequal to search WHO-prequalified medicines and their approved manufacturing sites
- Request the WHO-GMP certificate directly — A legitimate manufacturer will readily provide their current WHO-GMP certificate showing the scope, issue date, and validity period
- Cross-reference with CDSCO approvals — Verify that the manufacturer has a valid manufacturing license from the relevant state drug authority in India
- Look for international audit reports — Many reputable manufacturers voluntarily publish summaries of audits by the USFDA, MHRA (UK), TGA (Australia), or WHO
- Check the manufacturer’s presence on recognized industry directories — Membership in organizations like IMSDA indicates a commitment to quality and ethical practices
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA member directory. IMSDA members are required to maintain high standards of regulatory compliance and transparency.
🌍 What the Reforms Mean for International Buyers
India’s pharmaceutical regulatory landscape is undergoing its most significant transformation in decades. For international buyers, this creates both opportunity and responsibility:
- Better quality assurance — The revised Schedule M and CDSCO reforms mean that quality standards across Indian manufacturing are converging with international norms
- More documentation available — Enhanced data integrity requirements mean better traceability for each batch you purchase
- Higher compliance burden for small suppliers — Some small manufacturers may lose their licenses if they cannot meet the new standards, which is positive for quality but may reduce near-term supply options
- Due diligence remains essential — Despite regulatory progress, quality varies by facility. Always verify certification status directly
India supplies approximately 20% of the world’s generic medicines (GTRI, May 2026). With the regulatory reforms underway, the quality of those medicines has never been better documented or more thoroughly verified.
📋 Sources
- BioSpectrum India — “Why New Schedule M Is a Game Changer for Indian Pharma and How the Industry Is Adapting” (July 2025)
- Business Standard — “CDSCO tightens quality net with audits, scientific cadre overhaul” (February 2026)
- IndiaMedToday — “CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre” (February 2026)
- Medical Dialogues — “CDSCO, DoP Told to Find Workable Solution on Revised Schedule M GMP Concerns” (January 2026)
- Drishti IAS — “DCGI Directives on Global Standard GMP” (November 2025)
- Mint — “Govt mulls extension for pharma new manufacturing practice norms to bail out small firms” (December 2025)
- KNN India — “Govt Considers 1-Year Extension For Small Pharma Firms Ahead of Schedule M 2026 Rollout” (December 2025)
- Financial Express — “Weak compliance could force govt to extend the deadline for new pharma manufacturing rules” (December 2025)
- The Economic Times — “Drug companies in upgrade mode need more time for GMP compliance: IDMA” (December 2025)
- Moneycontrol — “Will remove rot of cough-syrup manufacturing by next production season: Central drug controller” (February 2026)
- GTRI (Global Trade Research Initiative) — Report on India’s 20% global generic medicine supply (May 2026)
- WHO — Guidelines on Good Manufacturing Practices (WHO Technical Report Series)
For more information, contact IMSDA at contact@indiamedicine.org.